Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose Stereotactic Radiosurgery (SDRT) as Definitive Non-Operative Treatment for Early-Stage Breast Cancer: A Prospective Single-Arm Pilot Trial With Bayesian Safety Monitoring (SOLIS / Protocol RAD 2024)

NCT07844759 is registered in ClinicalTrials.gov with Renaissance Institute of Precision Oncology and Radiosurgery as lead sponsor.

NCT NCT07844759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose Stereotactic Radiosurgery (SDRT) as Definitive Non-Operative Treatment for Early-Stage Breast Cancer: A Prospective Single-Arm Pilot Trial With Bayesian Safety Monitoring (SOLIS / Protocol RAD 2024)
Lead sponsor
Renaissance Institute of Precision Oncology and Radiosurgery
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
January 1, 2032
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early-stage breast carcinoma, her2-negative breast cancer, hormone receptor-positive breast cancer